Investigational drug · Phase 2
CYT-0851
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "CYT-0851"
First trial start
2019
Oct 9, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CYT-0851", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignancy
- Non-hodgkin Lymphoma
- Multiple Myeloma
- Breast Cancer
- Ovarian Cancer
- Soft Tissue Sarcoma
- Head and Neck Cancer
- DLBCL
- Mantle Cell Lymphoma
- Follicular Lymphoma
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Head and neck cancer · Sarcoma · Multiple myeloma · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CYT-0851" as an intervention, largest first.
Cyteir Therapeutics, Inc.Industry
NCT03997968 · 169 participants · Start Oct 9, 2019 · Primary completion Nov 30, 2024
Drug: CYT-0851; CYT-0851 in combination with gemcitabine and 2 more · For: Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma and 12 more
Sites: San Francisco, California; Stanford, California; Denver, Colorado · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Machine Learning-Guided Identification of Madecassoside as a Potential RAD51 Modulator That Sensitizes Breast Cancer Cells to Cisplatin.
Oh M, Jeong MY, Choi J · Chem Biol Drug Des 2026
- Preliminary Activity Seen with RAD51 Inhibitor.
· Cancer Discov 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.